WO1986000073A1 - Process for preparing adriamycine and halide salts thereof - Google Patents

Process for preparing adriamycine and halide salts thereof Download PDF

Info

Publication number
WO1986000073A1
WO1986000073A1 PCT/HU1984/000037 HU8400037W WO8600073A1 WO 1986000073 A1 WO1986000073 A1 WO 1986000073A1 HU 8400037 W HU8400037 W HU 8400037W WO 8600073 A1 WO8600073 A1 WO 8600073A1
Authority
WO
WIPO (PCT)
Prior art keywords
adriamycine
alkyl
daunomycine
derivative
solution
Prior art date
Application number
PCT/HU1984/000037
Other languages
French (fr)
Inventor
János BÁLINT
Szabolcs BORBÉLY
Zsuzsanna Emri
József FAZEKAS
György TÓTH
Original Assignee
BIOGAL Gyógyszergyár
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOGAL Gyógyszergyár filed Critical BIOGAL Gyógyszergyár
Priority to JP50256584A priority Critical patent/JPS61502956A/en
Priority to PCT/HU1984/000037 priority patent/WO1986000073A1/en
Priority to EP19840902361 priority patent/EP0183691A1/en
Publication of WO1986000073A1 publication Critical patent/WO1986000073A1/en
Priority to DK059486A priority patent/DK157082C/en
Priority to FI860683A priority patent/FI860683A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins

Definitions

  • This invention relates to a new process for preparing adriamycine and halide salts thereof.
  • adriamycine is an antitumor antibiotics which is used in the form of a halide for the treatment of tumouroua diseases.
  • Adriamycine can be produced directly by fermentation (Belgian Patent Specification Ho. 713,773) or by semisynthetic route from daunomycine (German Patent Specification No. 1,917,874 and US Patent Specification No. 4,012,448).
  • Adriamycine can be prepared by a more simple way from daunomycine through the 14-halo derivative of the latter, without changing the structure of the sugar moiety of the molecule (German patent specification No.
  • the bromination can directly be carried out by using a solution of bromine in chloroform, while in the course of iodination the amino group of the daunozamine is protected by transforming the latter into an acyl derivative or a Schiff base, thereafter the protecting group is removed and the adriamycine thus obtained is purified by column chromatography.
  • the simpliest way for preparing adriamycine from daunomycine by semi-synthetic route appears to be the direct bromination of daunomycine.
  • the daunozamine and the side-chain containing 14 carbon atoms can easily be splitted off, thus 14-bromodaunomycinone and other decomposition products without side-chain are formed.
  • the bromination reaction results in a rather low, i.e. 58-59 %, yield.
  • the yield based on the starting daunomycine is only about 6 to 13 %.
  • the present invention is aimed at developing a semi-synthetic process starting from daunomycine which enables to obtain adriamycine by a more simple and more economic way.
  • the process of the invention is carried out by reacting daunomycine or a halide salt thereof in an anhydrous organic solvent system in the presence of a solvent suitable for ketal formation, preferably in the presence of an alkyl ortoalkanecarboxylate or alkyl alkanoylate containing 1 to 6 carbon atoms in the alkyl moieties, with bromine, suitably at a temperature of 0 to 20 °C, preferably at 8 °C for 3 to 30 hours, preferably for 5 hours, thereafter transforming the formed 14-bromo derivative to the 14- hydroxy derivative in a manner known per se, optionally acidifying the solution with a haloid acid and recovering the product, optionally after purification.
  • a solvent suitable for ketal formation preferably in the presence of an alkyl ortoalkanecarboxylate or alkyl alkanoylate containing 1 to 6 carbon atoms in the alkyl moieties
  • bromine suitably at a temperature of 0 to 20 °C,
  • the triethyl orthoformate reacts with the enolic form of the 13- keto group of the daunomycine molecule formed due to the bromine being present, thus a ketal is produced which stabilizes the molecule, prohibites the side-reactions and the alkyl group cleavage.
  • the solvent suitable for ketal formation e.g. the triethyl orthoformate
  • the 11-bromodaunomycine derivative can be achieved in higher yields.
  • the 14- bromodaunomycine derivative need not to be recovered as the acetonic solution of 14-bromodaunomycine treated with hydrogen bromide can be directly used in a process where the bromo atom is replaced by a hrdroxyl group. This procedure can be carried out by a ranner well known in the art.
  • this process can more preferably be carried out through the 14-formyloxy derivative than by the direct conversion of the bromo atom to hydroxyl group by treating with sodium hydroxyde.
  • the hydrolysis of the 14-formyloxy derivative at pH 7.6 to 8.0 assures much more favourable conditions for the adriamycine being less resistant against alkaline agents than acids, than the basic treatment at pH 10.3.
  • the reaction mixture is preferably extracted with chloroform at pH 3.5 to 4.0 in order to remove the aglycone-type decomposition products.
  • the pH of 7.6 to 8.0 required to the hydrolysis is preferably adjusted with a 5 % by weight solution of sodium bicarbonate, the adriamycine base formed is recovered from the reaction mixture by repeated extraction with chloroform.
  • the extracts are concentrated, treated with a solution of hydrochloric acid in methanol in order to form adriamycine hydrochloride which is then precipitated from the solution with ether.
  • Adriamycine is used in the form of a halide salt for the preparation of medicaments, optionally after purification.
  • the purification is carried out in a manner known per se.
  • the reaction mixture is poured into a mixture of 230 ml. of diethyl ether and 120 ml. of petrol ether, the product precipitated is filtered off, washed with 3 x 30 ml. of diethyl ether in order to remove impurities. Then it is dissolved in a mixture of 40 ml. of acetone and 40 ml. of 0.25 N aqueous hydrogen bromide and kept at 25 °G for 17 hours. Thereafter a solution of 2.0 g. (29.4 millimoles) of sodium formate in 20 ml. of deionized water is added to the solution and stirred for 43 hours at 25 °C.
  • the pH of the reaction mixture is adjusted to 3.7 by adding 1 N hydrochloric acid solution and extracted with 50 ml. of chloroform five times. Then the pH of the aqueous phase is adjusted to 7.6 by adding a. 5 % solution of sodium bicarbonate and the adriamycine base is extracted from the mixture. The extraction is continued until the chloroformic extract is coloured.
  • the chloroformic extracts are washed with 5 To of deionized water, calculated for the volume of the extracts, and dried over anhydrous sodium sulphate. After the drying agent is filtered off, the solution is concentrated to a volume of 50 ml.
  • the free base is transformed to its hydrochloric salt by treating with a calculated amount of anhydrous hydrochloric acid solution in methanol and the salt is precipitated with 500 ml. of diethyl ether.
  • the product precipitated is filtered, washed four times with 30 ml. of diethyl ether and dried in vacuo at room temperature. Yield: 0.61 g, (42.4 % ) of adriamycine hydrochloride.
  • the analytical data of the product are listed below.
  • the pH of the reaction mixture is adjusted to 3.7 by adding 1 N hydrochloric solution and the mixture is extracted with chloroform five times. Then the pH of the aqueous layer is adjusted to 7.6 by adding a 5 % solution of sodium bicarbonate and the adriamycine base is recovered by extraction. The extraction is continued until the chloroformic extract becomes uncoloured.
  • the chloroformic extracts are washed with 5 To of deionized water, calculated for the volume of the extracts, then dried over anhydrous sodium sulphate. After filtering off the drying agent, the solution is concentrated in vacuo to a volume of 25 ml.
  • the free base is transformed into its hydrochloric salt by treating with a calculated amount of
  • Example 4 0.70 g. (1.24 mmoles) daunomycine hydrochloride are dissolved in a mixture of 10 ml. of anhydrous methyl alcohol, 30 ml. of dioxane and 0.8 ml. (4.35 mmoles) of triethyl orthoacetate. To the mixture thus obtained 0.25 g. (1.58 mmoles) of bromine in 2.7 ml, of anhydrous chloroform are added, the flask is closed and kept at 6 °C for 6 hours.
  • the reaction mixture is poured into a mixture of 140 ml. of diethyl ether and 60 ml. of petrol ether, the product precipitated is filtered off, the impurities are removed by washing with 3 x 15 ml. of diethyl ether.
  • the product is dissolved in a mixture of 20 ml. of acetone and 20 ml, of 0.25 N aqueous hydrogen bromide and kept at 25 °G for 17 hours. Then a solution of 1.0 g. (l4.7 mmoles) of sodium formate in 10 ml. of deionized water is added to the reaction mixture and the latter stirred at a temperature of 25 °C for 48 hours.
  • the identifying data of the end product are the same as indicated in Example 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The halide salts of adriamycine are useful antitumor antibiotics. Adriamycine and halide salts thereof are prepared with high yields from daunomycine or halide salts thereof by reacting daunomycine or a halide salt thereof with bromine in an anhydrous organic solvent system in the presence of a solvent suitable for ketal formation, transforming the formed 14-bromo derivative into a 14-hydroxy derivative in a manner known per se, optionally acidifying the solution with a haloid acid and recovering the product, optionally after purification.

Description

PROCESS FOR PREPARING ADRIAMYCINE AND HALIDE SALTS
THEREOF
Background of the invention
This invention relates to a new process for preparing adriamycine and halide salts thereof.
As it is well known from the art adriamycine is an antitumor antibiotics which is used in the form of a halide for the treatment of tumouroua diseases.
Adriamycine can be produced directly by fermentation (Belgian Patent Specification Ho. 713,773) or by semisynthetic route from daunomycine (German Patent Specification No. 1,917,874 and US Patent Specification No. 4,012,448).
The semi-synthetic processes starting from daunomycine and including the preparation of daunomycinone and 7-deoxydaunomycinone as intermediates are very complicated as not only the starting material has to be transformed in the course of the procedure, but the sugar component of adriamycine, the daunozamine has also to be bonded to the molecule.
Adriamycine can be prepared by a more simple way from daunomycine through the 14-halo derivative of the latter, without changing the structure of the sugar moiety of the molecule (German patent specification No.
1,917,374).
According to this process the bromination can directly be carried out by using a solution of bromine in chloroform, while in the course of iodination the amino group of the daunozamine is protected by transforming the latter into an acyl derivative or a Schiff base, thereafter the protecting group is removed and the adriamycine thus obtained is purified by column chromatography. The simpliest way for preparing adriamycine from daunomycine by semi-synthetic route appears to be the direct bromination of daunomycine. However, when reproducing this process, we found that the daunozamine and the side-chain containing 14 carbon atoms can easily be splitted off, thus 14-bromodaunomycinone and other decomposition products without side-chain are formed. Thus, the bromination reaction results in a rather low, i.e. 58-59 %, yield. In view of the fact that the molecule is sensitive to acids and bases and susceptible to oxidation, in the course of the replacement of the bromine atom of 14-bromodaunomycine by a hydroxyl group and when the purification of the products is effected further losses occur, thus the yield based on the starting daunomycine is only about 6 to 13 %.
The present invention is aimed at developing a semi-synthetic process starting from daunomycine which enables to obtain adriamycine by a more simple and more economic way.
Summary of the invention
The process of the invention is carried out by reacting daunomycine or a halide salt thereof in an anhydrous organic solvent system in the presence of a solvent suitable for ketal formation, preferably in the presence of an alkyl ortoalkanecarboxylate or alkyl alkanoylate containing 1 to 6 carbon atoms in the alkyl moieties, with bromine, suitably at a temperature of 0 to 20 °C, preferably at 8 °C for 3 to 30 hours, preferably for 5 hours, thereafter transforming the formed 14-bromo derivative to the 14- hydroxy derivative in a manner known per se, optionally acidifying the solution with a haloid acid and recovering the product, optionally after purification.
Detailed description of the invention
Surprisingly we found that if the bromination is carried out in the presence of a solvent suitable for ketal formation, e.g. in the presence of triethyl orthoformate, the molecule obtained is much more stable, deacetylation reaction does not occur, the glycosidic bond cleavage is fairly less, therefore the 14-bromodaunomycine derivative can be prepared in a substantially higher yield.
According to our experiments e.g. the triethyl orthoformate reacts with the enolic form of the 13- keto group of the daunomycine molecule formed due to the bromine being present, thus a ketal is produced which stabilizes the molecule, prohibites the side-reactions and the alkyl group cleavage.
The solvent suitable for ketal formation, e.g. the triethyl orthoformate, can preferably be used in a molar amount of 1 : 3-4, calculated for daunomycine or the hydrochloride salt thereof. Thus the 11-bromodaunomycine derivative can be achieved in higher yields. By using e.g. triethyl orthoacetate, methyl formate or ethyl acetate, similar good yields can also be achieved, According to the process of the invention the 14- bromodaunomycine derivative need not to be recovered as the acetonic solution of 14-bromodaunomycine treated with hydrogen bromide can be directly used in a process where the bromo atom is replaced by a hrdroxyl group. This procedure can be carried out by a ranner well known in the art.
According to our experiments this process can more preferably be carried out through the 14-formyloxy derivative than by the direct conversion of the bromo atom to hydroxyl group by treating with sodium hydroxyde. The hydrolysis of the 14-formyloxy derivative at pH 7.6 to 8.0 assures much more favourable conditions for the adriamycine being less resistant against alkaline agents than acids, than the basic treatment at pH 10.3.
Before the alkaline hydrolysis of 4-formyloxydaunomycine the reaction mixture is preferably extracted with chloroform at pH 3.5 to 4.0 in order to remove the aglycone-type decomposition products. The pH of 7.6 to 8.0 required to the hydrolysis is preferably adjusted with a 5 % by weight solution of sodium bicarbonate, the adriamycine base formed is recovered from the reaction mixture by repeated extraction with chloroform. The extracts are concentrated, treated with a solution of hydrochloric acid in methanol in order to form adriamycine hydrochloride which is then precipitated from the solution with ether.
Adriamycine is used in the form of a halide salt for the preparation of medicaments, optionally after purification. The purification is carried out in a manner known per se.
The present invention is illustrated by the aid of the following non-limiting examples.
Example 1
1.4 g. (2.43 millimoles) of daunomycine hydrochloride are dissolved in a mixture of 20 ml. of anhydrous methyl alcohol, 56 ml. of anhydrous dioxane and 1.4 ml. (3.47 millimoles) of anhydrous triethyl orthoformate. To the solution thus obtained 0.5 g. (3.16 millimoles) of bromine dissolved in 5.4 ml. of anhydrous chloroform are added, the flask is closed and kept at 3 °C for 5 hours.
The reaction mixture is poured into a mixture of 230 ml. of diethyl ether and 120 ml. of petrol ether, the product precipitated is filtered off, washed with 3 x 30 ml. of diethyl ether in order to remove impurities. Then it is dissolved in a mixture of 40 ml. of acetone and 40 ml. of 0.25 N aqueous hydrogen bromide and kept at 25 °G for 17 hours. Thereafter a solution of 2.0 g. (29.4 millimoles) of sodium formate in 20 ml. of deionized water is added to the solution and stirred for 43 hours at 25 °C.
The pH of the reaction mixture is adjusted to 3.7 by adding 1 N hydrochloric acid solution and extracted with 50 ml. of chloroform five times. Then the pH of the aqueous phase is adjusted to 7.6 by adding a. 5 % solution of sodium bicarbonate and the adriamycine base is extracted from the mixture. The extraction is continued until the chloroformic extract is coloured.
The chloroformic extracts are washed with 5 To of deionized water, calculated for the volume of the extracts, and dried over anhydrous sodium sulphate. After the drying agent is filtered off, the solution is concentrated to a volume of 50 ml. The free base is transformed to its hydrochloric salt by treating with a calculated amount of anhydrous hydrochloric acid solution in methanol and the salt is precipitated with 500 ml. of diethyl ether. The product precipitated is filtered, washed four times with 30 ml. of diethyl ether and dried in vacuo at room temperature. Yield: 0.61 g, (42.4 % ) of adriamycine hydrochloride. The analytical data of the product are listed below.
C27H29NO11.HCl (Mo lar weight: 530.0) Elsmentar analysis:
Calculated: C % = 55.9, H % = 5.21, N% = 2.42,
Cl % = 6.11
Found: C % = 55.52, H% = 5.10, N % = 2.04, Cl % = 6.24 Melting point: 202 - 206 °C (with decomposition) Thin-layer-chromatography: Adsorbent: Kieselgel 60 (Merck 5724) impregnated with a 1 % solution of oxalic acid Eluent: the upper layer of a 4:1:5 mixture of n-butanol/- acetic acid/water Development: 10 cm Rf value: 0.33
Infrared spectra: (Perkin-Elmer 397 type apparatus, -1
Figure imgf000008_0001
NMR:
( Bruker WP 200 SY impulse FT apparatus ; 1H-NMR, DMSO-d6, room temperature , delta ppm, 250 MHz )
Figure imgf000008_0002
C
Figure imgf000009_0001
x: changeable assignations
Example 2
1.4 g. (2.48 millimoles) of daunomycine hydrochloride are dissolved in a mixture of 40 ml. of anhydrous methyl alcohol and 0.55 ml. (8.7 mmoles) of anhydrous methyl formate. To the solution thus obtained 0.5 g. (3.16 mmoles) of bromine in 5.4 ml. of anhydrous chloroform are added, the flask is closed and kept at 10 °C for 4.5 hours. The reaction mixture is poured into a mixture of
280 ml, of diethyl ether and 120 ml. of petrolether, the product precipitated is filtered off, the impurities are removed by washing with 3 x 30 ml, of diethyl ether. The product is dissolved in a mixture of 40 ml. of acetone and 40 ml. of 0.25 N aqueous hydrogen bromide and kept at a temperature of 25 °C for 17 hours. Then a solution of 2.0 g. (29.4 mmoles) of sodium formate in 20 ml. of deionized water is added to the reaction mixture and the solution is stirred for 48 hours at 25 °C.
The reaction mixture thus obtained is worked up according to Example 1.
Yield: 0.55 g. (38,6 % ) The identifying data of the end product are the same as given in Example 1, Example 3
0,70 g. (1,24 mmoles) of daunomycine hydrochloride are dissolved in a mixture of 10 ml, of anhydrous methyl alcohol, 30 ml, of anhydrous dioxane and 0,42 ml, (4.30 mmoles) of ethyl acetate. To the solution thus obtained 0,25 g. (l.58 mmoles) of bromine in 2.7 ml. of anhydrous chloroform are added, the flask is closed and kept at 6°C for 6 hours. The reaction mixture is poured into a mixture of 140 ml. of diethyl ether and 60 ml. of petrol ether, the product precipitated is filtered off and the impurities are removed by washing with 3 x 15 ml. of diethyl ether. The product is dissolved in a mixture of 20 ml, of acetone and 20 ml, of 0,25 N aqueous hydrogen bromide and kept at a temperature of 25 °C for 17 hours. Thereafter a solution of 1,0 g, (14,7 mmoles) of sodium formate in 10 ml, of deionized water is added to the reaction mixture and the latter is stirred at 25 °C for 48 hours.
The pH of the reaction mixture is adjusted to 3.7 by adding 1 N hydrochloric solution and the mixture is extracted with chloroform five times. Then the pH of the aqueous layer is adjusted to 7.6 by adding a 5 % solution of sodium bicarbonate and the adriamycine base is recovered by extraction. The extraction is continued until the chloroformic extract becomes uncoloured. The chloroformic extracts are washed with 5 To of deionized water, calculated for the volume of the extracts, then dried over anhydrous sodium sulphate. After filtering off the drying agent, the solution is concentrated in vacuo to a volume of 25 ml. The free base is transformed into its hydrochloric salt by treating with a calculated amount of
0.6 N anhydrous methanolic hydrochloric solution, thereafter the salt is precipitated by 250 ml. of diethyl ether. The product precipitated is filtered off, washed with 15 ml, of diethyl ether four times and dried in vacuo at room temperature.
Yield: 0.29 g. (40.3 %)
The identifying data are the same as indicated in Example 1. Example 4 0.70 g. (1.24 mmoles) daunomycine hydrochloride are dissolved in a mixture of 10 ml. of anhydrous methyl alcohol, 30 ml. of dioxane and 0.8 ml. (4.35 mmoles) of triethyl orthoacetate. To the mixture thus obtained 0.25 g. (1.58 mmoles) of bromine in 2.7 ml, of anhydrous chloroform are added, the flask is closed and kept at 6 °C for 6 hours.
The reaction mixture is poured into a mixture of 140 ml. of diethyl ether and 60 ml. of petrol ether, the product precipitated is filtered off, the impurities are removed by washing with 3 x 15 ml. of diethyl ether. The product is dissolved in a mixture of 20 ml. of acetone and 20 ml, of 0.25 N aqueous hydrogen bromide and kept at 25 °G for 17 hours. Then a solution of 1.0 g. (l4.7 mmoles) of sodium formate in 10 ml. of deionized water is added to the reaction mixture and the latter stirred at a temperature of 25 °C for 48 hours.
The reaction mixture thus obtained is worked up according to Example 3.
Yield: 0.30 g. (41.7 % )
The identifying data of the end product are the same as indicated in Example 1.

Claims

What we claim is:
1. Process for the preparation of adriamycine and the halide salts thereof from daunomycine or the halide salts thereof which comprises reacting daunomycine or a halide salt thereof with bromine in an anhydrous organic solvent system in the presence of a solvent suitable for ketal formation, then transforming the formed 14-bromo derivative into a 14-hydroxy derivative in a manner known per se, optionally acidifying the solution with a haloid acid and recovering the product, optionally after purification.
2. The process of claim 1 wherein the bromination is carried out at 0 to 20 °C, preferably at 8 °C, for 3 to 30 hours, preferably for 5 hours.
3. The process of claim 1 or 2 wherein an alkyl orthoalkanecarboxylate or alkyl alkanoylate containing 1 to 6 carbon atoms in the alkyl moieties is used as solvent suitable for ketal formation.
4. The process of claim 3 wherein triethyl orthoformate is used as alkyl orthoalkanecarboxilate.
5. The process of claim 3 wherein ethyl acetate is used as alkyl alkanoylate.
6. The process of any of the preceeding claims wherein a mixture of methanol and dioxane of 1 : 2-5 volume rate is used as anhydrous organic solvent system.
7. The process of any of the preceeding claims wherein the transformation of the 14-bromo derivative to the 14-hydroxy derivative is carried out by precipitating the 14-bromo derivative in an organic solvent system, then reacting with hydrogen bromide in the presence of acetone and an alkaline formate, preferably sodium formate, extracting the reaction mixture thus obtained in two steps with chloroform by adjusting the pH and recovering the product optionally as a halide salt.
PCT/HU1984/000037 1984-06-14 1984-06-14 Process for preparing adriamycine and halide salts thereof WO1986000073A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50256584A JPS61502956A (en) 1984-06-14 1984-06-14 Method for preparing adriamycin and its halide salts
PCT/HU1984/000037 WO1986000073A1 (en) 1984-06-14 1984-06-14 Process for preparing adriamycine and halide salts thereof
EP19840902361 EP0183691A1 (en) 1984-06-14 1984-06-14 Process for preparing adriamycine and halide salts thereof
DK059486A DK157082C (en) 1984-06-14 1986-02-06 PROCEDURE FOR THE PREPARATION OF ADRIAMYCINE AND ITS HALOGENEAL SALTS
FI860683A FI860683A0 (en) 1984-06-14 1986-02-14 FOERFARANDE FOER FRAMSTAELLNING AV ADRIAMYCIN OCH HALIDSALTER DAERAV.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU1984/000037 WO1986000073A1 (en) 1984-06-14 1984-06-14 Process for preparing adriamycine and halide salts thereof

Publications (1)

Publication Number Publication Date
WO1986000073A1 true WO1986000073A1 (en) 1986-01-03

Family

ID=10980572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1984/000037 WO1986000073A1 (en) 1984-06-14 1984-06-14 Process for preparing adriamycine and halide salts thereof

Country Status (5)

Country Link
EP (1) EP0183691A1 (en)
JP (1) JPS61502956A (en)
DK (1) DK157082C (en)
FI (1) FI860683A0 (en)
WO (1) WO1986000073A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358161A2 (en) * 1988-09-06 1990-03-14 Sanraku Incorporated Novel anthracycline derivatives and process for production thereof
EP0363604A2 (en) * 1988-10-11 1990-04-18 Sicor Societa' Italiana Corticosteroidi S.P.A. Improved process for the conversion of daunorubicin into doxorubicin
US5026691A (en) * 1987-03-30 1991-06-25 The Upjohn Company Combination of minoxidil and an antiinflammatory agent for treating patterned alopecia
US7388083B2 (en) 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
ITMI20090784A1 (en) * 2009-05-08 2010-11-09 Antibioticos Spa PROCEDURE FOR THE PREPARATION OF 14-BROMO DAUNOMICINA
ITMI20100007A1 (en) * 2010-01-08 2011-07-09 Antibioticos Spa PROCESS FOR THE PREPARATION OF DOXORUBICINE
US8357785B2 (en) 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
US8802830B2 (en) 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US9035032B2 (en) 2005-12-13 2015-05-19 Solux Corporation Method for preparing 4-demethyldaunorubicin

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT848009E (en) 1996-12-16 2000-11-30 Pharmachemie Bv PROCESS FOR THE PREPARATION OF EPIRUBICIN OR ITS SALTS OF ADDITION OF ACID FROM DAUNORUBICIN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT283597B (en) * 1968-04-12 1970-08-10 Farmaceutici Italia Process for the preparation of adriamycin and adriamycinone
DE2652391A1 (en) * 1975-11-18 1977-05-26 Farmaceutici Italia DAUNOSAMINYLANTHRACYCLINONE, METHOD OF MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
AT358736B (en) * 1976-12-22 1980-09-25 Erba Farmitalia METHOD FOR PRODUCING NEW ANTITUM ORGLYCOSIDES
EP0039060A1 (en) * 1980-04-26 1981-11-04 Zaidanhojin Biseibutsu Kagaku Kenkyukai A new method for preparation of anthracycline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT283597B (en) * 1968-04-12 1970-08-10 Farmaceutici Italia Process for the preparation of adriamycin and adriamycinone
DE2652391A1 (en) * 1975-11-18 1977-05-26 Farmaceutici Italia DAUNOSAMINYLANTHRACYCLINONE, METHOD OF MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
AT358736B (en) * 1976-12-22 1980-09-25 Erba Farmitalia METHOD FOR PRODUCING NEW ANTITUM ORGLYCOSIDES
EP0039060A1 (en) * 1980-04-26 1981-11-04 Zaidanhojin Biseibutsu Kagaku Kenkyukai A new method for preparation of anthracycline derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026691A (en) * 1987-03-30 1991-06-25 The Upjohn Company Combination of minoxidil and an antiinflammatory agent for treating patterned alopecia
EP0358161A2 (en) * 1988-09-06 1990-03-14 Sanraku Incorporated Novel anthracycline derivatives and process for production thereof
EP0358161A3 (en) * 1988-09-06 1990-07-11 Sanraku Incorporated Novel anthracycline derivatives and process for production thereof
US4997922A (en) * 1988-09-06 1991-03-05 Sanraku Incorporated Anthracycline derivatives
EP0363604A2 (en) * 1988-10-11 1990-04-18 Sicor Societa' Italiana Corticosteroidi S.P.A. Improved process for the conversion of daunorubicin into doxorubicin
EP0363604A3 (en) * 1988-10-11 1990-07-25 Sicor Societa' Italiana Corticosteroidi S.P.A. Improved process for the conversion of daunorubicin into doxorubicin
US7388083B2 (en) 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
US9035032B2 (en) 2005-12-13 2015-05-19 Solux Corporation Method for preparing 4-demethyldaunorubicin
US8802830B2 (en) 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US8357785B2 (en) 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
ITMI20090784A1 (en) * 2009-05-08 2010-11-09 Antibioticos Spa PROCEDURE FOR THE PREPARATION OF 14-BROMO DAUNOMICINA
ITMI20100007A1 (en) * 2010-01-08 2011-07-09 Antibioticos Spa PROCESS FOR THE PREPARATION OF DOXORUBICINE

Also Published As

Publication number Publication date
JPS61502956A (en) 1986-12-18
FI860683A (en) 1986-02-14
FI860683A0 (en) 1986-02-14
DK59486D0 (en) 1986-02-06
DK59486A (en) 1986-02-06
DK157082C (en) 1990-04-09
EP0183691A1 (en) 1986-06-11
DK157082B (en) 1989-11-06

Similar Documents

Publication Publication Date Title
JP2751385B2 (en) Process for producing erythromycin A oxime and its salt
JPH08208681A (en) Production of sucrose derivative
JPH0212478B2 (en)
WO1986000073A1 (en) Process for preparing adriamycine and halide salts thereof
JP3983803B2 (en) Production of anthracycline antibiotics
IE46165B1 (en) Daunomycinone derivatives
EP0678501B1 (en) Process for producing N-chloroacetylglutamine
JP2843592B2 (en) L-ribose derivative
EP0053919B1 (en) Cephamycin c derivative and its preparation
JPH0742304B2 (en) Novel anthracycline derivative and method for producing the same
US5220002A (en) Deacetylcolchicine derivatives
KR950013771B1 (en) Process for preparing 14-chlorodaunomyan and (2"r)-4'-0-tetrahydropyranyladriamyin
EP0483754B1 (en) Novel process for producing 6-(3-dimethylaminopropionyl)forskolin
KR850001961B1 (en) Process for manufacturing 3'-acylated macrolide antibiotics
JP3134010B2 (en) Desalanine benanomycin A derivatives and methods for their production
KR850000528B1 (en) Method of preparing for antracycline derivate
NO860500L (en) PROCEDURE FOR THE PREPARATION OF ADRIAMYCIN AND THE HALOGENIDE SALTS THEREOF.
JP2894366B2 (en) Method for producing deacetylcolchicine
KR930001165B1 (en) Process for the preparation of 4'-deoxydoxorubicin
JP2579678B2 (en) Anthracycline derivative and method for producing the same
US5463040A (en) Method of preparing etoposide
JPH0481599B2 (en)
JP3398176B2 (en) Decomposition method of cephalosporin prodrug ester to 7-amino-3-methoxymethylcef-3-em-4-carboxylic acid
WO1981000409A1 (en) Intermediate compounds for preparation of morphine derivatives
KR830002481B1 (en) 3" - acylated macrolide antibiotics

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK FI JP NO RO SU US

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO RO SU US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1984902361

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 860683

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1984902361

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1984902361

Country of ref document: EP